SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC  20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 24, 2006

 

Array BioPharma Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

000-31979

 

84-1460811

(State or Other

 

(Commission

 

(IRS Employer

Jurisdiction of

 

File Number)

 

Identification No.)

Incorporation)

 

 

 

 

 

 

 

 

 

3200 Walnut Street, Boulder, Colorado

 

80301

(Address of Principal Executive Offices)

 

(Zip Code)

 

 

 

 

 

Registrant’s telephone number, including area code: (303) 381-6600

 

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o                                                           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                                                           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                                                           Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                                                           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

ITEM 8.01. OTHER EVENTS

 

On January 24, 2006, Array issued a press release announcing that AstraZeneca PLC had selected an additional clinical candidate for their small molecule anticancer program, triggering a $1 million milestone payment from AstraZeneca to Array, the full text of which is attached hereto as Exhibit 99.1.

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

 

(c) Exhibits.

 

99.1

 

Press release dated January 24, 2006 entitled “Array BioPharma Achieves Milestone for Selection of Second Clinical Candidate for MEK Anticancer Program.”

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ARRAY BIOPHARMA INC.

 

 

 

 

 

 

Date:  January 24, 2006

By:

  /s/ Robert E. Conway

 

 

 

Robert E. Conway

 

 

Chief Executive Officer

 

3


 

EXHIBIT INDEX

 

Exhibit No.

 

 

 

 

 

99.1

 

Press release dated January 24, 2006 entitled “Array BioPharma Achieves Milestone for Selection of Second Clinical Candidate for MEK Anticancer Program.”

4